齐拉西酮与利醅酮治疗精神分裂症的对照研究

A Comparative Study between Ziprasidone and Resperidone in Treatment of Schizophrenia

目的:比较齐拉西酮和利醅酮治疗精神分裂症的疗效和安全性。方法:将68例精神分裂症患者随机分为两组,分别给予齐拉西酮和利醅酮治疗8周。采用阳性症状与阴性症状量表(PANSS)评定临床疗效,症状量表(TESS)评定不良反应。结果:齐拉西酮和利醅酮治疗8周有效率分别为88.2%和85.3%,两药疗效的差异无统计学意义(P>0.05)。齐拉西酮组的不良反应发生率稍低于利醅酮组,利醅酮组锥体外系反应和内分泌改变的发生率均显著高于齐拉西酮组(P<0.05),但两药引起的不良反应一般为轻度或中度,患者耐受性较好。结论:齐拉西酮和利醅酮对精神分裂症的疗效相当,但不良反应有所不同。

Objective：To compare the efficacy and safety of ziprasidone and resperidone in treatment of schizophrenia.Methods：Sixty-eight patients with schizophrenia were randomly assigned to two groups treated with ziprasidone or resperidone for 8 weeks.The positive and negative symptom scale（PANSS） and treatment emergent symptoms scale（TESS） were used to evaluate the efficacy and adverse effects.Results：The total effective rates of ziprasidone and resperidone were 88.2% and 85.3% respectively after 8 weeks treatments.There was no significant difference between two groups（P0.05）.Incidence of adverse effects in ziprasidone group was lower than in resperidone group.The rates of extrapyramidal symptoms and endocrine change were significant higher in resperidone group than those in ziprasidone group（P0.05）.But these side effects were not serious,and patients often had good tolerance for them.Conclusion：It is suggested that ziprasidone is an effective drug for schizophrenia,with light side effects.